Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov-Dec;71(6):434-439.
doi: 10.1016/j.ihj.2019.11.259. Epub 2019 Dec 3.

QT prolongation in HIV-positive patients: Review article

Jing Liu  1 , Sumit K Shah  2 , Indranill Basu-Ray  3 , Julia Garcia-Diaz  4 , Kainat Khalid  5 , Mohammad Saeed  6
Affiliations
Review

QT prolongation in HIV-positive patients: Review article

Jing Liu et al. Indian Heart J. 2019 Nov-Dec.

Abstract

Introduction: Antiretrovirals have immensely increased the average life expectancy of HIV-positive patients. However, the incidence of QT interval prolongation and other arrhythmias has also increased.

Methods: Pubmed and Google Scholar were searched for relevant literature published between 1990 and 2019.

Results and discussion: HIV-positive patients with high viral load, low CD4 count, chronic inflammation, and autonomic neuropathy can develop QT interval prolongation. Another factor prolonging QT interval includes exposure to the HIV transactivator protein, which inhibits hERG K (+) channels controlling IKr K (+) currents in cardiomyocytes. Protease inhibitors inhibiting the CYP3A4 enzyme can also lead to QT interval prolongation. QT interval prolongation can potentially be exacerbated by opioids, antipsychotics, antibiotics, and antifungals, the adjunct medications often used in HIV-positive patients. Hepatic insufficiency in seropositive patients on antiretrovirals may also increase the risk of QT interval prolongation.

Conclusion: Baseline and follow-up EKG in the susceptible population is suggested.

Keywords: Antiretroviral; HIV-positive; QT-interval; Sudden cardiac death; Torsades de pointes.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest The authors have no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. The Antiretroviral Therapy Cohort Collaboration Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372:293–299. - PMC - PubMed
    1. Andrieux-Meyer I., Calmy A., Cahn P. Art Sequencing meeting September 22–23, 2011, Geneva, Switzerland. Preferred antiretroviral drugs for the next decade of scale up. J Int AIDS Soc. 2012;15:17986. - PMC - PubMed
    1. Palella F.J., Jr., Baker R.K., Moorman A.C. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27–34. - PubMed
    1. Schouten E.G., Dekker J.M., Meppelink P., Kok F.J., Vandenbroucke J.P., Pool J. QT interval prolongation predicts cardiovascular mortality in an apparently healthy population. Circulation. 1991;84:1516–1523. - PubMed
    1. Elming H., Holm E., Jun L. The prognostic value of the QT interval and QT interval dispersion in all-cause and cardiac mortality and morbidity in a population of Danish citizens. Eur Heart J. 1998;19:1391–1400. - PubMed

MeSH terms